96 Tests PN: B113387

Components:

45x Ab-conjugated beads (S4P9 - human sE-Cadherin Ab-bead). PN: B113387A. One vial containing 100 µL of anti-human sE-Cadherin conjugated to AimPlex Bead S4P9.

25x Biotin-detection Ab (human sE-Cadherin Biotin-dAb). PN: B113387B. One vial containing 100 µL of biotinylated anti-human sE-Cadherin.

Lyophilized Standard Mix-Human Group 5 Panel A, 8-Plex. PN: HG50008. One vial containing lyophilized recombinant human sE-Cadherin, sLIGHT, sTRAIL-R3, s4-1BB, sCD30L, sVEGFR2, BlyS, and sPECAM-1. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Application: Optimal antibody pair and antigen standard for assaying human E-Cadherin/CDH1/sCD324. Can be multiplexed with other analytes in Human Group 5.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma (EDTA plasma is not recommended.), bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 5 pg/mL

  • Quantitation range:

  • LLOQ: < 10 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 5: Negligible

  • Sample volume: 15 µL/test

Description:

Cadherin-1 (CDH1), also known as CAM 120/80 or epithelial cadherin (E-Cadherin), is a protein that has also been designated as CD324 and is a tumor suppressor gene. Loss of E-Cadherin function has been implicated in cancer progression and metastasis. E-cadherin downregulation decreases the strength of cellular adhesion within a tissue, resulting in an increase in cellular motility. This in turn may allow cancer cells to cross the basement membrane and invade surrounding tissues. E-cadherin is also used by pathologists to diagnose different kinds of breast cancer. When compared with invasive ductal carcinoma, E-cadherin expression is markedly reduced or absent in the great majority of invasive lobular carcinomas when studied by immunohistochemistry. Diseases associated with CDH1 include familial gastric cancer and gastric linitis plastica.

References:

  1. Huntsman DG, Caldas C (Mar 1999). "Assignment1 of the E-cadherin gene (CDH1) to chromosome 16q22.1 by radiation hybrid mapping". Cytogenet Cell Genet 83 (1-2): 82–3. doi:10.1159/000015134. PMID 9925936.

  2. Semb H, Christofori G (December 1998). "The tumor-suppressor function of E-cadherin". Am. J. Hum. Genet. 63 (6): 1588–93. doi:10.1086/302173. PMC 1377629. PMID 9837810.

  3. Wong AS, Gumbiner BM (June 2003). "Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin". J. Cell Biol. 161 (6): 1191–203. doi:10.1083/jcb.200212033. PMC 2173007. PMID 12810698.

  4. Beavon, IR (August 2000). "The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation.". European journal of cancer (Oxford, England: 1990) 36 (13 Spec No): 1607–20. doi:10.1016/S0959-8049(00)00158-1. PMID 10959047. Retrieved 17 November 2015.

.